Clinical Value of LncRNA MEG3 in High-Grade Serous Ovarian Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Apr 17

PMID 32295169

Citations 21

Authors

Marianna Buttarelli

Marta De Donato

Giuseppina Raspaglio

Gabriele Babini

Alessandra Ciucci

Enrica Martinelli

Pina Baccaro

Tina Pasciuto

Anna Fagotti

Giovanni Scambia

Daniela Gallo

Affiliations

Soon will be listed here.

Abstract

Long non-coding RNAs (lncRNAs) are emerging as regulators in cancer development and progression, and aberrant lncRNA profiles have been reported in several cancers. Here, we evaluated the potential of using the maternally expressed gene 3 (MEG3) tissue level as a prognostic marker in high-grade serous ovarian cancer (HGSOC), the most common and deadliest gynecologic malignancy. To the aim of the study, we measured MEG3 transcript levels in 90 pre-treatment peritoneal biopsies. We also investigated MEG3 function in ovarian cancer biology. We found that high MEG3 expression was independently associated with better progression-free ( = 0.002) and overall survival ( = 0.01). In vitro and in vivo preclinical studies supported a role for MEG3 as a tumor suppressor in HGSOC, possibly through modulation of the phosphatase and tensin homologue (PTEN) network. Overall, results from this study demonstrated that decreased MEG3 is a hallmark for malignancy and tumor progression in HGSOC.

Citing Articles

A Comprehensive Bioinformatic Analysis Identifies a Tumor Suppressor Landscape of the MEG3 lncRNA in Breast Cancer.

Ahmadi A, Rezaei A, Khalaj-Kondori M, Khajehdehi M Indian J Surg Oncol. 2024; 15(4):752-761.

PMID: 39555361 PMC: 11564602. DOI: 10.1007/s13193-024-01992-0.

Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer.

Ju H, Youn S, Kang J, Whang M, Choi Y, Han M Biomark Res. 2024; 12(1):80.

PMID: 39135097 PMC: 11318304. DOI: 10.1186/s40364-024-00632-7.

mA methylation-mediated regulation of LncRNA MEG3 suppresses ovarian cancer progression through miR-885-5p and the VASH1 pathway.

Li Y, Lou S, Zhang J, Zhao S, Lou G J Transl Med. 2024; 22(1):113.

PMID: 38281945 PMC: 10823642. DOI: 10.1186/s12967-024-04929-x.

Imprinted Long Non-Coding RNAs in Mammalian Development and Disease.

Di Michele F, Chillon I, Feil R Int J Mol Sci. 2023; 24(17).

PMID: 37686455 PMC: 10487962. DOI: 10.3390/ijms241713647.

PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer.

Chen B, Lu X, Zhou Q, Chen Q, Zhu S, Li G PLoS One. 2023; 18(8):e0290031.

PMID: 37582104 PMC: 10426951. DOI: 10.1371/journal.pone.0290031.

References

Prislei S, Martinelli E, Zannoni G, Petrillo M, Filippetti F, Mariani M . Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer. Oncotarget. 2015; 6(22):18966-79. PMC: 4662468. DOI: 10.18632/oncotarget.3943. View

Wang L, Wang C, Jin S, Qu D, Ying H . Expression of NF-κB and PTEN in primary epithelial ovarian carcinoma and the correlation with chemoresistance. Int J Clin Exp Pathol. 2015; 8(9):10953-63. PMC: 4637628. View

Meryet-Figuiere M, Lambert B, Gauduchon P, Vigneron N, Brotin E, Poulain L . An overview of long non-coding RNAs in ovarian cancers. Oncotarget. 2016; 7(28):44719-44734. PMC: 5190131. DOI: 10.18632/oncotarget.8089. View

Anglesio M, Wiegand K, Melnyk N, Chow C, Salamanca C, Prentice L . Type-specific cell line models for type-specific ovarian cancer research. PLoS One. 2013; 8(9):e72162. PMC: 3762837. DOI: 10.1371/journal.pone.0072162. View

Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V . Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. Eur J Cancer. 2016; 59:22-33. DOI: 10.1016/j.ejca.2016.01.017. View

Ward M, McEwan C, Mills J, Janitz M . Conservation and tissue-specific transcription patterns of long noncoding RNAs. J Hum Transcr. 2016; 1(1):2-9. PMC: 4894084. DOI: 10.3109/23324015.2015.1077591. View

Workman P, Aboagye E, Balkwill F, Balmain A, Bruder G, Chaplin D . Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010; 102(11):1555-77. PMC: 2883160. DOI: 10.1038/sj.bjc.6605642. View

Huarte M . The emerging role of lncRNAs in cancer. Nat Med. 2015; 21(11):1253-61. DOI: 10.1038/nm.3981. View

Colombo P, Fabbro M, Theillet C, Bibeau F, Rouanet P, Ray-Coquard I . Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol. 2013; 89(2):207-16. DOI: 10.1016/j.critrevonc.2013.08.017. View

10.

Hallas-Potts A, Dawson J, Herrington C . Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas. Sci Rep. 2019; 9(1):5515. PMC: 6445084. DOI: 10.1038/s41598-019-41941-4. View

11.

Kim J, Park E, Kim O, Schilder J, Coffey D, Cho C . Cell Origins of High-Grade Serous Ovarian Cancer. Cancers (Basel). 2018; 10(11). PMC: 6267333. DOI: 10.3390/cancers10110433. View

12.

Sheng X, Li J, Yang L, Chen Z, Zhao Q, Tan L . Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer. Oncol Rep. 2014; 32(1):277-85. DOI: 10.3892/or.2014.3208. View

13.

Khudayberdiev S, Zampa F, Rajman M, Schratt G . A comprehensive characterization of the nuclear microRNA repertoire of post-mitotic neurons. Front Mol Neurosci. 2013; 6:43. PMC: 3840315. DOI: 10.3389/fnmol.2013.00043. View

14.

Prensner J, Chinnaiyan A . The emergence of lncRNAs in cancer biology. Cancer Discov. 2011; 1(5):391-407. PMC: 3215093. DOI: 10.1158/2159-8290.CD-11-0209. View

15.

Zhang J, Liu J, Xu X, Li L . Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer. Cancer Chemother Pharmacol. 2017; 79(3):479-487. DOI: 10.1007/s00280-017-3238-4. View

16.

Wang L, Yu M, Zhao S . lncRNA MEG3 modified epithelial-mesenchymal transition of ovarian cancer cells by sponging miR-219a-5p and regulating EGFR. J Cell Biochem. 2019; 120(10):17709-17722. DOI: 10.1002/jcb.29037. View

17.

Chen J, Peng X, Dai Y . The Long Non-Coding RNA (lncRNA) AGAP2-AS1 is Upregulated in Ovarian Carcinoma and Negatively Regulates lncRNA MEG3. Med Sci Monit. 2019; 25:4699-4704. PMC: 6604673. DOI: 10.12659/MSM.914766. View

18.

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A . Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7):RESEARCH0034. PMC: 126239. DOI: 10.1186/gb-2002-3-7-research0034. View

19.

Rustin G, Marples M, Nelstrop A, Mahmoudi M, Meyer T . Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol. 2001; 19(20):4054-7. DOI: 10.1200/JCO.2001.19.20.4054. View

20.

Yang H, Kong W, He L, Zhao J, ODonnell J, Wang J . MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008; 68(2):425-33. DOI: 10.1158/0008-5472.CAN-07-2488. View